Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
2.590
-0.110 (-4.07%)
At close: Apr 28, 2026, 4:00 PM EDT
2.680
+0.090 (3.47%)
After-hours: Apr 28, 2026, 6:45 PM EDT
Alaunos Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Alaunos Therapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Alaunos Therapeutics.
Recommendation Trends
| Rating | Mar '23 | Apr '23 | May '23 | Jun '23 | Jul '23 | Aug '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 16, 2023 |
| Laidlaw & Co. | Laidlaw & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 15, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $225 | Hold → Strong Buy | Upgrades | $225 | +8,587.26% | May 15, 2023 |
| Wells Fargo | Wells Fargo | Buy Initiates $450 | Buy | Initiates | $450 | +17,274.52% | Mar 27, 2023 |
| Wells Fargo | Wells Fargo | Buy Initiates $450 | Buy | Initiates | $450 | +17,274.52% | Oct 4, 2022 |
Financial Forecast
Revenue This Year
n/a
from 5.00K
Revenue Next Year
n/a
EPS This Year
-0.14
from -2.20
EPS Next Year
n/a
from -0.14
Revenue Forecast
| Revenue | 2026 |
|---|---|
| High | n/a |
| Avg | n/a |
| Low | n/a |
Revenue Growth
| Revenue Growth | 2026 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
EPS Forecast
| EPS | 2026 |
|---|---|
| High | -0.15 |
| Avg | -0.14 |
| Low | -0.14 |
EPS Growth
| EPS Growth | 2026 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.